Your browser doesn't support javascript.
loading
A ring N(CH3)2-based derivative of resveratrol inhibits pulmonary vascular remodeling in hypoxia pulmonary hypertension.
Kong, Shuang; Yu, Jiang; Li, Han-Fei; Xie, Yu-Liang; Song, Liao-Fan; Wang, Qian-Qian; Chen, Yu-Jing; Zhao, Fan-Rong; Zhang, Wei-Fang; Zhu, Tian-Tian.
Afiliação
  • Kong S; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Yu J; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Li HF; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Xie YL; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Song LF; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Wang QQ; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Chen YJ; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Zhao FR; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
  • Zhang WF; Departments of Pharmacy, The Second Affiliated Hospital, Nanchang University, Nanchang, 330006, China. Electronic address: z_weifang@163.com.
  • Zhu TT; College of Pharmacy, Xinxiang Medical University, Xinxiang, 453003, China; Henan International Joint Laboratory of Cardiovascular Remodeling and Drug Intervention, Xinxiang, 453003, China; Xinxiang Key Laboratory of Vascular Remodeling Intervention and Molecular Targeted Therapy Drug Development, Xi
Eur J Pharmacol ; 959: 176077, 2023 Nov 15.
Article em En | MEDLINE | ID: mdl-37820784
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipertensão Pulmonar Limite: Animals Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Hipertensão Pulmonar Limite: Animals Idioma: En Revista: Eur J Pharmacol Ano de publicação: 2023 Tipo de documento: Article